Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper.
Hypertension is the most important cardiovascular risk factor. We have witnessed a significant improvement in hypertension treatment and control and an impressive growth in the pharmacologic options available to clinicians and hypertension specialists. With up to a third of patients with hypertension not at the recommended goal blood pressures, it is critically important to develop novel therapeutic approaches to better treat hypertension. This review will explore the ever-expanding horizon of antihypertensive treatment and will focus on 2 major areas of drug development. First, we will review novel targets for pharmacologic treatment and novel molecules and classes of drugs in various phases of development and recognize the limitations we face in their transition from research and development to clinical practice. Then, we will discuss an expanding array of combination strategies to better treat hypertension with the goal of minimizing the burden of cardiovascular and renal complications of hypertension.
Department of Medicine, Baylor College of Medicine, Houston, TX, USA gabehabib@yahoo.com.
Gabriel B
GB
Habib
Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Sukhdeep S
SS
Basra
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D055808:Drug Discovery; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
D000959:Antihypertensive Agents
endothelin-converting enzyme; fixed low-dose combination drugs; hypertension; renin–angiotensin–aldosterone system; vasopeptidase inhibitors